Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245516 · ClinicalTrials.gov registry record · NA
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
A NA study, sponsored by Kala Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT02245516 is a NA study that has completed, run by Kala Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT02245516, a NA study, has completed, sponsored by Kala Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or Diabetic Macular Edema.
Interventions
- DRUG KPI-121 0.25% Ophthalmic Suspension
- DRUG KPI-121 1.0% Ophthalmic Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02245516
The ClinicalTrials.gov registry entry for NCT02245516 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kala Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KPI-121 0.25% Ophthalmic Suspension is the first listed.
NCT02245516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02245516 about?
NCT02245516 is a clinical study titled "Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema". The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or Diabetic Macular Edema.
What is the current status of trial NCT02245516?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2014-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02245516?
The interventions under investigation include: KPI-121 0.25% Ophthalmic Suspension (DRUG), KPI-121 1.0% Ophthalmic Suspension (DRUG).
Who is sponsoring clinical trial NCT02245516?
This trial is sponsored by Kala Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.